US Genetic Testing Market Size to Hit USD 10.29 Billion by 2027
07 oct. 2022 07h28 HE
|
Fortune Business Insights
Pune, India, Oct. 07, 2022 (GLOBE NEWSWIRE) -- The US Genetic Testing Market size is expected to achievement momentum by reaching USD 10.29 billion by 2027 while exhibiting an impressive CAGR of...
Global Genetic Testing Market Analysis & Forecasts, 2016-2021 & 2022-2031: Predictive, Carrier, Prenatal and Newborn, Diagnostic, Pharmacogenomic, & Nutrigenomic Testing
06 oct. 2022 06h08 HE
|
Research and Markets
Dublin, Oct. 06, 2022 (GLOBE NEWSWIRE) -- The "Genetic Testing Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.The global genetic testing market is expected to...
Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds
28 sept. 2022 09h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a nationwide survey it conducted...
Global Rare Disease Genetic Testing Market Report 2022: Government & Regulatory Support for Rare Disease Diagnosis to Drive Growth
16 sept. 2022 04h28 HE
|
Research and Markets
Dublin, Sept. 16, 2022 (GLOBE NEWSWIRE) -- The "Rare Disease Genetic Testing Market Size, Share & Trends Analysis Report by Disease Type (Neurological, CVDs), by Specialty (Molecular,...
Florida Cancer Specialists & Research Institute Celebrates Addition of Next-Generation Genomic Testing Capabilities to Advance Precision Oncology Approach to Patient Care
06 sept. 2022 12h26 HE
|
Florida Cancer Specialists & Research Institute
Fort Myers, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLC (FCS) celebrated the addition of genomic testing capabilities at its Next Generation...
Novo estudo publicado no Clinical Cancer Research Journal destaca o uso do teste EndoPredict para informar o tratamento em pacientes com câncer de mama na pré-menopausa
31 août 2022 08h00 HE
|
Myriad Genetics, Inc.
O teste EndoPredict, da Myriad Genetics, identificou com precisão mulheres na pré-menopausa com câncer de mama ER+, HER2- que poderiam evitar, com segurança, a quimioterapia adjuvante SALT LAKE CITY,...
Nuevo estudio publicado en Clinical Cancer Research Journal destaca el uso de la prueba EndoPredict para informar el tratamiento en pacientes premenopáusicas con cáncer de mama
31 août 2022 08h00 HE
|
Myriad Genetics, Inc.
La prueba EndoPredict de Myriad Genetics identificó con precisión a mujeres premenopáusicas con cáncer de mama ER+, HER2- que podrían evitar la quimioterapia adyuvante de forma segura SALT LAKE CITY,...
Un nuovo studio pubblicato sulla rivista Clinical Cancer Research mette in evidenza l’impiego del test EndoPredict per indicare quale trattamento adottare in pazienti con tumore al seno in premenopausa
31 août 2022 08h00 HE
|
Myriad Genetics, Inc.
Il test EndoPredict di Myriad Genetics ha identificato in modo accurato le donne in premenopausa con carcinoma mammario ER+, HER2- che potevano con sicurezza evitare la chemioterapia adiuvante SALT...
Neue Studie, im Clinical Cancer Research Journal veröffentlicht, unterstreicht die Bedeutung des EndoPredict-Tests zur Information über die Behandlung von prämenopausalen Brustkrebs-Patientinnen
31 août 2022 08h00 HE
|
Myriad Genetics, Inc.
Myriad Genetics’ EndoPredict-Test identifiziert präzise prämenopausale Frauen mit ER+, HER2-Brustkrebs, die eine adjuvante Chemotherapie vermeiden können SALT LAKE CITY, Aug. 31, 2022 (GLOBE...
New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients
31 août 2022 08h00 HE
|
Myriad Genetics, Inc.
Myriad Genetics’ EndoPredict test accurately identified premenopausal women with ER+, HER2- breast cancer who could safely avoid adjuvant chemotherapy SALT LAKE CITY, Aug. 31, 2022 (GLOBE NEWSWIRE)...